N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study
Open Access
- 1 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 14 (3), R143
- https://doi.org/10.1186/ar3876
Abstract
Pulmonary arterial hypertension is a major cause of mortality in systemic sclerosis. N-terminal pro-brain natriuretic peptide (NT-proBNP) has emerged as a candidate biomarker that may enable the early detection of systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). The objective of our study was to incorporate NT-proBNP into a screening algorithm for SSc-PAH that could potentially replace transthoracic echocardiography (TTE) as a more convenient and less costly "first tier" test.This publication has 31 references indexed in Scilit:
- Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long‐term survivalArthritis & Rheumatism, 2011
- Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEALChest, 2010
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals Of The Rheumatic Diseases, 2010
- Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcomeRheumatology, 2010
- Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafilRheumatology, 2009
- Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosisInternal Medicine Journal, 2009
- Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment EraAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialThe Lancet, 2008
- Changes in causes of death in systemic sclerosis, 1972-2002Annals Of The Rheumatic Diseases, 2007
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals Of The Rheumatic Diseases, 2006